0.27 0.09 <0.01 0.95 0.84 BASDAI (0-10), mean +/-SD [N=2,082] 5.0 ± 2.4 5.8 ± 2.1 4.7 ± 2.4 <0.01 ASDAS-CRP, mean +/-SD [N=1,534] ASDAS inactive disease, n (%) ASDAS moderate disease activity, n (%) ASDAS high disease activity, n (%) ASDAS very high disease activity, n (%)
3.2 ± 1.1 82 (5) 160 (10) 684 (45) 608 (40) 3.5 ± 1.0 9 (2) 28 (5) 272 (46) 285 (48) 3. 3.6 ± 1.0 4 (1) 22 (5) 203 (44) 234 (51) 3.8 ± 0.9 0 (0) 5 (2) Online Supplementary Table S6 . Response to bDMARD in patients fulfilling the ASAS axSpA Classification Criteria within the ‚efficacy population' according to the BASDAI/ASDAS category Overall (ASAS 'efficacy population'): axSpA patients according to ASAS criteria, treated with bDMARD, with complete 6 months of follow-up and complete data on all response outcomes (every time point). Estimated probability of response across all subgroups according to BASDAI/ASDAS category of disease activity using a logistic regression model adjusted for age, gender, CRP and BASFI. * Models fail to converge. 95% CI, 95% confidence interval. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. ASDAS, Ankylosing Spondylitis Disease Activity Score. ASAS PR, ASAS Partial Remission. ASDAS CII, ASDAS Clinical Important improvement. ASAS MI, ASDAS Major Improvement. 
Variables

